<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>FROVA- frovatriptan succinate tablet, film coated </strong><br>Unit Dose Services<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer"><span class="Bold"><span class="Bold">These highlights do not include all the information needed to use FROVA
                <span class="Sup">®</span></span><span class="Bold">safely and effectively.  See full prescribing information for FROVA
                <span class="Sup">®</span></span><span class="Bold">.
                <br><br></span><span class="Bold">FROVA
                <span class="Sup">®</span></span><span class="Bold">(frovatriptan succinate) tablets, for oral use
                <br></span><span class="Bold">Initial U.S. Approval:  2001</span></span></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta"> Warnings and Precautions ( )          11/2012
                                    <a href="#LINK_e293fcd4-96c4-4393-8ddf-cec3e8cf073a">5.6</a> </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">FROVA is a serotonin (5-HT ) receptor agonist (triptan) indicated for the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> in adults ( )
                                    <span class="Sub">1B/1D</span><a href="#LINK_885295a3-c501-4980-9a58-aa9d84887342">1</a> </p>
<p class="Highlighta"><span class="Underline">Limitations of Use</span> </p>
<ul class="Disk">
<li>Use only after a clear diagnosis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> has been established ( )
                                        <a href="#LINK_885295a3-c501-4980-9a58-aa9d84887342">1</a>
</li>
<li>Not indicated for the <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> therapy of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> ( )
                                        <a href="#LINK_885295a3-c501-4980-9a58-aa9d84887342">1</a>
</li>
<li>Not indicated for the treatment of <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headache</span> ( )
                                        <a href="#LINK_885295a3-c501-4980-9a58-aa9d84887342">1</a>
</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disk"><li>1 tablet taken with fluids.  Second tablet may be taken 2 hours after initial dose if <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> recurs following initial relief.  Total dose not to exceed 3 tablets in any 24-hour period ( )
                                        <a href="#LINK_665f5d97-4d25-4586-b2f1-5d3e8d51cf85">2</a>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets:  2.5 mg ( )
                                    <a href="#LINK_aa08cb21-9c9c-4f11-999f-2c7d871011c4">3</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disk">
<li>History of <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> or coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> ( )
                                        <a href="#LINK_12cd4ef2-79d2-406e-a549-15548debcebb">4</a>
</li>
<li>Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders ( )
                                        <a href="#LINK_12cd4ef2-79d2-406e-a549-15548debcebb">4</a>
</li>
<li>History of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, transient ischemic attack, or hemiplegic or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> ( )
                                        <a href="#LINK_12cd4ef2-79d2-406e-a549-15548debcebb">4</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">Peripheral vascular disease</span> ( )
                                        <a href="#LINK_12cd4ef2-79d2-406e-a549-15548debcebb">4</a>
</li>
<li>Ischemic bowel disease ( )
                                        <a href="#LINK_12cd4ef2-79d2-406e-a549-15548debcebb">4</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">Uncontrolled hypertension</span> ( )
                                        <a href="#LINK_12cd4ef2-79d2-406e-a549-15548debcebb">4</a>
</li>
<li>Recent (within 24 hours) use of treatment with another 5-HT agonist, or an ergotamine-containing medication ( )
                                        <span class="Sub">1</span><a href="#LINK_12cd4ef2-79d2-406e-a549-15548debcebb">4</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to FROVA (<span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> seen) ( )
                                        <a href="#LINK_12cd4ef2-79d2-406e-a549-15548debcebb">4</a>
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disk">
<li><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial ischemia</span>/<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> or Prinzmetal’s angina:  Perform cardiac evaluation in patients with multiple cardiovascular risk factors ( )
                                            <a href="#LINK_87a7b537-4900-4e58-ba02-36b2cc7ae264">5.1</a> </p></li>
<li><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span>:Discontinue FROVA if occurs ( )
                                            <a href="#LINK_b222c1ac-4794-4ae0-972d-dd36bab90284">5.2</a> </p></li>
<li><p class="Highlighta">Chest/throat/neck/<span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">jaw pain</span>, tightness, pressure, or heaviness:Generally not associated with <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>; evaluate high risk patients for <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> ( )
                                            <a href="#LINK_857e1be3-21b0-4db8-988c-5fcd8b326b20">5.3</a> </p></li>
<li><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">Cerebral hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>: Discontinue FROVA if occurs ( )
                                            <a href="#LINK_0f5a86c8-9aba-4622-b8bc-5655902910c5">5.4</a> </p></li>
<li><p class="Highlighta">Gastrointestinal ischemic reactions and peripheral vasospastic reactions: Discontinue FROVA if occurs ( )
                                            <a href="#LINK_56de01ef-1231-4672-bb67-a3d877257436">5.5</a> </p></li>
<li><p class="Highlighta">Medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>:Detoxification may be necessary ( )
                                            <a href="#LINK_e293fcd4-96c4-4393-8ddf-cec3e8cf073a">5.6</a> </p></li>
<li><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span>:Discontinue FROVA if occurs ( , )
                                            <a href="#LINK_d9d35ee9-ca30-4276-a75e-cb3211ca2357">5.7</a><a href="#LINK_70973a58-9917-4e1a-8ff0-0af5224c2f8a">7.3</a> </p></li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disk"><li><p class="Highlighta">Most common adverse reactions (≥2% and &gt;placebo) were <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, hot or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sensation, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">skeletal pain</span>, and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>  ( )
                                            <a href="#LINK_5def9706-b694-4f6f-aad9-e7a0d969a6b3">6.1</a> </p></li></ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Endo Pharmaceuticals Inc. at 1-800-462-3636 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disk"><li> Pregnancy: Based on animal data, may cause fetal harm ( )
                                        <a href="#LINK_c9051e96-6a54-4b4a-8cba-0def75f4877e">8.1</a>
</li></ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 10/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">1 INDICATIONS AND USAGE</span></a></h1>
<h1><a href="#section-2" class="toc"><span class="Bold">2 DOSAGE AND ADMINISTRATION</span></a></h1>
<h1><a href="#section-3" class="toc"><span class="Bold">3 DOSAGE FORMS AND STRENGTHS</span></a></h1>
<h1><a href="#section-4" class="toc"><span class="Bold">4 CONTRAINDICATIONS</span></a></h1>
<h1><a href="#section-5" class="toc"><span class="Bold">5 WARNINGS AND PRECAUTIONS</span></a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>,  and Prinzmetal’s Angina</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Chest, Throat, Neck, and <span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">Jaw Pain</span>/Tightness/Pressure</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Cerebrovascular Events</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">Vasospasm</span> Reactions</a></h2>
<h2><a href="#section-5.6" class="toc">5.6  Medication Overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Increase in Blood Pressure</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></a></h2>
<h1><a href="#section-6" class="toc"><span class="Bold">6 ADVERSE REACTIONS</span></a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc"><span class="Bold">7 DRUG INTERACTIONS</span></a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Ergot-containing Drugs</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 5-HT Agonists
                                <span class="Sub">1B/1D</span></a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Selective Serotonin Reuptake Inhibitors / Serotonin Norepinephrine Reuptake Inhibitors and <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></a></h2>
<h1><a href="#section-8" class="toc"><span class="Bold">8 USE IN SPECIFIC POPULATIONS</span></a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">10 OVERDOSAGE</span></a></h1>
<h1><a href="#section-10" class="toc"><span class="Bold">11 DESCRIPTION</span></a></h1>
<h1><a href="#section-11" class="toc"><span class="Bold">12 CLINICAL PHARMACOLOGY</span></a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc"><span class="Bold">13 NONCLINICAL TOXICOLOGY</span></a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">14 CLINICAL STUDIES</span></a></h1>
<h1><a href="#section-14" class="toc"><span class="Bold">16 HOW SUPPLIED/STORAGE AND HANDLING</span></a></h1>
<h1><a href="#section-15" class="toc"><span class="Bold">17 PATIENT COUNSELING INFORMATION</span></a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_885295a3-c501-4980-9a58-aa9d84887342"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">1 INDICATIONS AND USAGE</span></h1>
<p class="First">FROVA is indicated for the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> in adults.</p>
<p><span class="Underline">Limitations of Use</span></p>
<ul class="Disk">
<li><p class="First">Use only if a clear diagnosis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> has been established. If a patient has no response for the first <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack treated with FROVA, reconsider the diagnosis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> before FROVA is administered to treat any subsequent attacks.</p></li>
<li><p class="First">FROVA is not indicated for the prevention of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks.</p></li>
<li><p class="First">Safety and effectiveness of FROVA have not been established for <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headache</span>.</p></li>
</ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_665f5d97-4d25-4586-b2f1-5d3e8d51cf85"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">2 DOSAGE AND ADMINISTRATION</span></h1>
<p class="First"><span class="Bold">Dosing Information
                                <br></span></p>
<p>The recommended dose is a single tablet of FROVA (frovatriptan 2.5 mg) taken orally with fluids.</p>
<p>If the <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> recurs after initial relief, a second tablet may be taken, providing there is an interval of at least 2 hours between doses. The total daily dose of FROVA should not exceed 3 tablets (3 x 2.5 mg per 24 hour period).</p>
<p>There is no evidence that a second dose of FROVA is effective in patients who do not respond to a first dose of the drug for the same <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
<p>The safety of treating an average of more than 4 <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks in a 30-day period has not been established.</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="LINK_aa08cb21-9c9c-4f11-999f-2c7d871011c4"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">3 DOSAGE FORMS AND STRENGTHS</span></h1>
<p class="First">2.5 mg Tablets:  Round, white, film-coated tablets debossed with 2.5 on one side and "E" on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_12cd4ef2-79d2-406e-a549-15548debcebb"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">4 CONTRAINDICATIONS</span></h1>
<p class="First">FROVA is contraindicated in patients with:</p>
<ul class="Disk">
<li><p class="First">Ischemic <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (CAD) (e.g. <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, or documented silent <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>), or coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>, including Prinzmetal’s angina
                                    <span class="Italics">[see Warnings and Precautions ( )].
                                        <a href="#LINK_87a7b537-4900-4e58-ba02-36b2cc7ae264">5.1</a></span></p></li>
<li><p class="First">Wolff-Parkinson-White Syndrome or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> associated with other cardiac accessory conduction pathway disorders
                                    <span class="Italics">[see Warnings and Precautions ( )].
                                        <a href="#LINK_b222c1ac-4794-4ae0-972d-dd36bab90284">5.2</a></span></p></li>
<li><p class="First">History of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, transient ischemic attack (TIA), or history of hemiplegic or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> because these patients are at a higher risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>
                                    <span class="Italics">[s</span><span class="Italics">ee Warnings and Precautions ( )].
                                        <a href="#LINK_0f5a86c8-9aba-4622-b8bc-5655902910c5">5.4</a></span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">Peripheral vascular disease</span>
                                    <span class="Italics">[s</span><span class="Italics">ee Warnings and Precautions ( )].
                                        <a href="#LINK_56de01ef-1231-4672-bb67-a3d877257436">5.5</a></span></p></li>
<li><p class="First">Ischemic bowel disease
                                    <span class="Italics">[s</span><span class="Italics">ee Warnings and Precautions ( )].
                                        <a href="#LINK_56de01ef-1231-4672-bb67-a3d877257436">5.5</a></span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">Uncontrolled hypertension</span>
                                    <span class="Italics">[see Warnings and Precautions ( )].
                                        <a href="#LINK_4fdf5f3e-5c81-4c7c-b9ff-d1841c63b984">5.8</a></span></p></li>
<li><p class="First">Recent use (i.e., within 24 hours) of another 5-HT agonist, an ergotamine containing or ergot-type medication such as dihydroergotamine (DHE) or methysergide
                                    <span class="Sub">1</span><span class="Italics">[see Drug Interactions ( , )].
                                        <a href="#LINK_34918c27-9b47-48fa-991b-3d55ce303526">7.1</a><a href="#LINK_18ac9908-cf72-45c5-ae5b-9dc2bd855397">7.2</a></span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to FROVA (<span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> seen)
                                    <span class="Italics">[s</span><span class="Italics">ee Warnings and Precautions ( )].
                                        <a href="#LINK_6adf6145-2f2b-4fb5-beae-631573914a98">5.9</a></span></p></li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_79c0b0f6-affa-4166-86aa-f7bc0eb0e4fa"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">5 WARNINGS AND PRECAUTIONS</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_87a7b537-4900-4e58-ba02-36b2cc7ae264"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>,  and Prinzmetal’s Angina</h2>
<p class="First">FROVA is contraindicated in patients with ischemic or vasospastic CAD. There have been rare reports of serious cardiac adverse reactions, including <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, occurring within a few hours following administration of FROVA. Some of these reactions occurred in patients without known CAD. FROVA may cause coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> (Prinzmetal’s angina), even in patients without a history of CAD.</p>
<p>Perform a cardiovascular evaluation in triptan-naïve patients who have multiple cardiovascular risk factors (e.g., increased age, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, smoking, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, strong family history of CAD) prior to receiving FROVA.  Do not administer FROVA if there is evidence of CAD or coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> [ ]. For patients with multiple cardiovascular risk factors who have a negative cardiovascular evaluation, consider administrating the first FROVA dose in a medically-supervised setting and performing an electrocardiogram (ECG) immediately following FROVA administration.  For such patients, consider periodic cardiovascular evaluation in intermittent long-term users of FROVA.
                                    <span class="Italics">see Contraindications ( )
                                        <a href="#LINK_12cd4ef2-79d2-406e-a549-15548debcebb">4</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b222c1ac-4794-4ae0-972d-dd36bab90284"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span></h2>
<p class="First">Life-threatening disturbances of cardiac rhythm including <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported within a few hours following the administration of 5-HT agonists.  Discontinue FROVA if these disturbances occur.  FROVA is contraindicated in patients with Wolff-Parkinson-White syndrome or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> associated with other cardiac accessory conduction pathway disorders
                                    <span class="Sub">1</span><span class="Italics">[see Contraindications ( )].
                                        <a href="#LINK_12cd4ef2-79d2-406e-a549-15548debcebb">4</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_857e1be3-21b0-4db8-988c-5fcd8b326b20"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Chest, Throat, Neck, and <span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">Jaw Pain</span>/Tightness/Pressure</h2>
<p class="First">Sensations of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, tightness, pressure, and heaviness have been reported in the chest, throat, neck, and jaw after treatment with FROVA and are usually non-cardiac in origin.  However, perform a cardiac evaluation if these patients are at high cardiac risk.  The use of FROVA is contraindicated in patients with CAD and those with Prinzmetal’s angina [ ].
                                    <span class="Italics">see Contraindications ( )
                                        <a href="#LINK_12cd4ef2-79d2-406e-a549-15548debcebb">4</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0f5a86c8-9aba-4622-b8bc-5655902910c5"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Cerebrovascular Events</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">Cerebral hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and other cerebrovascular events have been reported in patients treated with 5-HT agonists, and some have resulted in fatalities. In a number of cases, it appears possible that the cerebrovascular events were primary, the agonist having been administered in the incorrect belief that the symptoms experienced were a consequence of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, when they were not.
                                    <span class="Sub">1</span></p>
<p>Before treating <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> in patients not previously diagnosed as migraineurs, and in migraineurs who present with symptoms atypical of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, other potentially serious neurological conditions need to be excluded. FROVA is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or TIA
                                    <span class="Italics">[see Contraindications ( )].
                                        <a href="#LINK_12cd4ef2-79d2-406e-a549-15548debcebb">4</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_56de01ef-1231-4672-bb67-a3d877257436"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">Vasospasm</span> Reactions</h2>
<p class="First">FROVA, may cause non-coronary vasospastic reactions, such as peripheral vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, gastrointestinal vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> and <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> (presenting with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>), <span class="product-label-link" type="condition" conceptid="4044745" conceptname="Splenic infarction">splenic infarction</span>, and Raynaud’s syndrome. In patients who experience symptoms or signs suggestive of a vasospastic reaction following the use of any 5-HT agonist, rule out a vasospastic reaction before using FROVA [ ].
                                    <span class="Sub">1</span><span class="Italics">see Contraindications ( )
                                        <a href="#LINK_12cd4ef2-79d2-406e-a549-15548debcebb">4</a></span></p>
<p>Reports of transient and permanent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> and significant partial <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span> have been reported with the use of 5-HT agonists. Since visual disorders may be part of a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack, a causal relationship between these events and the use of 5-HT agonists have not been clearly established.
                                    <span class="Sub">1</span><span class="Sub">1</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e293fcd4-96c4-4393-8ddf-cec3e8cf073a"></a><a name="section-5.6"></a><p></p>
<h2>5.6  Medication Overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></h2>
<p class="First">Overuse of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">acute migraine</span> drugs (e.g., ergotamine, triptans, opioids, or combination of these drugs for 10 or more days per month) may lead to exacerbation of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>). Medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> may present as <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>-like daily <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> or as a marked increase in frequency of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks. Detoxification of patients, including withdrawal of the overused drugs, and treatment of withdrawal symptoms (which often includes a transient worsening of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>) may be necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d9d35ee9-ca30-4276-a75e-cb3211ca2357"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> may occur with FROVA, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase (MAO) inhibitors [ ]. <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> symptoms may include <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>), neuromuscular aberrations (e.g., <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>), and/or <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>). The onset of symptoms usually occurs within minutes to hours of receiving a new or a greater dose of a serotonergic medication. Discontinue FROVA if <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> is suspected.
                                    <span class="Italics">see Drug Interactions ( )
                                        <a href="#LINK_70973a58-9917-4e1a-8ff0-0af5224c2f8a">7.3</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4fdf5f3e-5c81-4c7c-b9ff-d1841c63b984"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Increase in Blood Pressure</h2>
<p class="First">Significant elevation in blood pressure, including <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span> with acute impairment of organ systems, has been reported on rare occasions in patients treated with 5-HT agonists, including patients without a history of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.  Monitor blood pressure in patients treated with FROVA.  FROVA is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span>
                                    <span class="Sub">1</span><span class="Italics">[see Contraindications ( )].
                                        <a href="#LINK_12cd4ef2-79d2-406e-a549-15548debcebb">4</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6adf6145-2f2b-4fb5-beae-631573914a98"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></h2>
<p class="First">There have been reports of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, anaphylactoid, and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> in patients receiving FROVA. Such reactions can be life threatening or fatal.  In general, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to drugs are more likely to occur in individuals with a history of sensitivity to multiple allergens.  FROVA is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to FROVA
                                    <span class="Italics">[see Contraindications ( )].
                                        <a href="#LINK_12cd4ef2-79d2-406e-a549-15548debcebb">4</a></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_f6b9e885-8fd5-4005-85f8-283a770ebe4f"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">6 ADVERSE REACTIONS</span></h1>
<p class="First"> The following adverse reactions are described elsewhere in other sections of the labeling:</p>
<ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and Prinzmetal’s angina
                                <span class="Italics">[see Warnings and Precautions ( )]
                                    <a href="#LINK_87a7b537-4900-4e58-ba02-36b2cc7ae264">5.1</a></span>
</li>
<li><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span>
                                <span class="Italics">[see Warnings and Precautions ( )]
                                    <a href="#LINK_b222c1ac-4794-4ae0-972d-dd36bab90284">5.2</a></span>
</li>
<li>Chest, throat, neck and/or <span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">jaw pain</span>/tightness/pressure
                                <span class="Italics">[see Warnings and Precautions</span><span class="Italics">( )]
                                    <a href="#LINK_857e1be3-21b0-4db8-988c-5fcd8b326b20">5.3</a></span>
</li>
<li>Cerebrovascular events
                                <span class="Italics">[see Warnings and Precautions ( )]
                                    <a href="#LINK_0f5a86c8-9aba-4622-b8bc-5655902910c5">5.4</a></span>
</li>
<li>Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> reactions
                                <span class="Italics">[see Warnings and Precautions ( )]
                                    <a href="#LINK_56de01ef-1231-4672-bb67-a3d877257436">5.5</a></span>
</li>
<li>Medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>
                                <span class="Italics">[see Warnings and Precautions ( )]
                                    <a href="#LINK_e293fcd4-96c4-4393-8ddf-cec3e8cf073a">5.6</a></span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span>
                                <span class="Italics">[see Warnings and Precautions</span><span class="Italics">( )]
                                    <a href="#LINK_d9d35ee9-ca30-4276-a75e-cb3211ca2357">5.7</a></span>
</li>
<li>Increases in blood pressure
                                <span class="Italics">[see Warnings and Precautions ( )]
                                    <a href="#LINK_4fdf5f3e-5c81-4c7c-b9ff-d1841c63b984">5.8</a></span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>
                                <span class="Italics">[see Contraindications ( ) and Warnings and Precautions ( )]
                                    <a href="#LINK_12cd4ef2-79d2-406e-a549-15548debcebb">4</a><a href="#LINK_4fdf5f3e-5c81-4c7c-b9ff-d1841c63b984">5.8</a></span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5def9706-b694-4f6f-aad9-e7a0d969a6b3"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>FROVA was evaluated in four randomized, double-blind, placebo-controlled, short-term trials. These trials involved 2392 patients (1554 on FROVA 2.5 mg and 838 on placebo). In these short-term trials, patients were predominately female (88%) and Caucasian (94%) with a mean age of 42 years (range 18 - 69).The treatment-emergent adverse events that occurred most frequently following administration of FROVA 2.5 mg ( in at least 2% of patients), and at an incidence ≥1% greater than with placebo, were <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, hot or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sensation, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">skeletal pain</span>, and <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>. In a long term, open-label study where 496 patients were allowed to treat multiple <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks with FROVA 2.5 mg for up to 1 year, 5% of patients (n=26) discontinued due to treatment-emergent adverse events.
                                    <span class="Italics">i.e.,</span></p>
<p>Table 1 lists treatment-emergent adverse events reported within 48 hours of drug administration that occurred with FROVA 2.5 mg at an incidence of ≥2% and more often than on placebo, in the four placebo-controlled trials. The events cited reflect experience gained under closely monitored conditions of clinical trials in a highly selected patient population. In actual clinical practice or in other clinical trials, these incidence estimates may not apply, as the conditions of use, reporting behavior, and the kinds of patients treated may differ.</p>
<p><span class="Bold">Table 1
                                        <br></span></p>
<span class="Bold">Treatment-Emergent Adverse Events Reported within 48 Hours (Incidence ≥</span><span class="Bold">2% and Greater Than Placebo) of Patients in Four Pooled Placebo-Controlled <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> Trials
                                    <br></span><table>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Adverse events</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">FROVA 2.5 mg</span></p>
<p>(n=1554)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
<p>(n=838)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Italics">Central &amp; peripheral nervous system</span></p>
<p><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>
                                                    <span class="Italics">  </span></p>
<p>   <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p>
<p>   <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span>        </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">8%</p>
<p>4%</p>
<p>4%</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">5%</p>
<p>3%</p>
<p>2%</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Italics">Gastrointestinal system disorders</span></p>
<p><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span>
                                                    <span class="Italics"> </span></p>
<p>  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">3%</p>
<p>2%</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">1%</p>
<p>1%</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Italics">Body as a whole – general disorders</span></p>
<p><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>
                                                    <span class="Italics"> </span></p>
<p>  Hot or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> sensation</p>
<p>  <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">5%</p>
<p>3%</p>
<p>2%</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First">2%</p>
<p>2%</p>
<p>1%</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Italics">Musculo-skeletal</span></p>
<p>  <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">Skeletal pain</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">3%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Italics">Vascular</span></p>
<p>  <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2%</p></td>
</tr>
</tbody>
</table>
<p>The incidence of adverse events in clinical trials did not increase when up to 3 doses were used within 24 hours. The incidence of adverse events in placebo-controlled clinical trials was not affected by gender, age or concomitant medications commonly used by <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> patients. There were insufficient data to assess the impact of race on the incidence of adverse events.</p>
<p><span class="Italics"><span class="Underline">Other Events Observed in Association with the Administration of FROVA</span></span></p>
<p>The incidence of frequently reported adverse events in four placebo-controlled trials are presented below. Events are further classified within body system categories. Frequent adverse events are those occurring in at least 1/100 patients.</p>
<p><span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesia</span> and <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>.
                                    <span class="Italics">Central and peripheral nervous system:</span></p>
<p><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.
                                    <span class="Italics">Gastrointestinal:</span></p>
<p><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.
                                    <span class="Italics">Body as a whole:</span></p>
<p><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> and <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>.
                                    <span class="Italics">Psychiatric:</span></p>
<p><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span> and <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>.
                                    <span class="Italics">Respiratory:</span></p>
<p><span class="product-label-link" type="condition" conceptid="4265433" conceptname="Visual impairment">vision abnormal</span>.
                                    <span class="Italics">Vision disorders</span><span class="Italics">:</span></p>
<p><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating increased</span>.
                                    <span class="Italics">Skin and appendages:</span></p>
<p><span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>.
                                    <span class="Italics">Hearing and <span class="product-label-link" type="condition" conceptid="81303" conceptname="Labyrinthine disorder">vestibular disorders</span>:</span></p>
<p><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>.
                                    <span class="Italics">Heart rate and rhythm:</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_eb7fd0d0-fa27-4145-a6e5-7e4f7b773594"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions were identified during post approval use of FROVA. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>:  <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span>.
                                    <span class="Italics">Central and peripheral nervous system</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_8667e39a-6a11-4be9-8866-b674b7f01167"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">7 DRUG INTERACTIONS</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_34918c27-9b47-48fa-991b-3d55ce303526"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Ergot-containing Drugs</h2>
<p class="First">Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other is contraindicated [ ].
                                    <span class="Italics">see Contraindications ( )
                                        <a href="#LINK_12cd4ef2-79d2-406e-a549-15548debcebb">4</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_18ac9908-cf72-45c5-ae5b-9dc2bd855397"></a><a name="section-7.2"></a><p></p>
<h2>7.2 5-HT Agonists
                                <span class="Sub">1B/1D</span>
</h2>
<p class="First">Because their vasospastic effects may be additive, co-administration of FROVA and other 5-HT agonists (e.g., triptans) within 24 hours of each other is contraindicated [ ].
                                    <span class="Sub">1</span><span class="Italics">see Contraindications ( )
                                        <a href="#LINK_12cd4ef2-79d2-406e-a549-15548debcebb">4</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_70973a58-9917-4e1a-8ff0-0af5224c2f8a"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Selective Serotonin Reuptake Inhibitors / Serotonin Norepinephrine Reuptake Inhibitors and <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> have been reported during combined use of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [ ].
                                    <span class="Italics">see Warnings and Precautions ( )
                                        <a href="#LINK_d9d35ee9-ca30-4276-a75e-cb3211ca2357">5.7</a></span></p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_8910d4f6-7ebd-4a7e-9182-de54587a770a"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">8 USE IN SPECIFIC POPULATIONS</span></h1>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_c9051e96-6a54-4b4a-8cba-0def75f4877e"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category C: There are no adequate and well-controlled trials in pregnant women; therefore, frovatriptan should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>When pregnant rats were administered frovatriptan during the period of organogenesis at oral doses of 100, 500 and 1000 mg/kg/day (equivalent to 130, 650 and 1300 times the maximum recommended human dose [MRHD] of 7.5 mg/day on a mg/m basis) there were dose related increases in incidences of fetuses with dilated ureters, unilateral and bilateral pelvic cavitation, <span class="product-label-link" type="condition" conceptid="433811" conceptname="Hydronephrosis">hydronephrosis</span>, and <span class="product-label-link" type="condition" conceptid="194408" conceptname="Hydroureter">hydroureters</span>. A no-effect dose for renal effects was not established. This signifies a syndrome of related effects on a specific organ in the developing embryo in all treated groups, which is consistent with a slight delay in fetal maturation. This delay was also indicated by a treatment related increased incidence of incomplete ossification of the sternebrae, skull and nasal bones in all treated groups. Reduced fetal weights and an increased incidence of embryolethality were observed in treated rats; an increase in embryolethality occurred in both the embryo-fetal developmental study and in the prenatal-postnatal developmental study. No increase in embryolethality was observed at the lowest dose level studied (100 mg/kg/day, equivalent to 130 times the MRHD on a mg/m basis). When pregnant rabbits were dosed throughout organogenesis at oral doses up to 80 mg/kg/day (equivalent to 210 times the MRHD on a mg/m basis), no effects on fetal development were observed.
                                    <span class="Sup">2</span><span class="Sup">2</span><span class="Sup">2</span></p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_2d9af56a-1e92-4b1c-9bac-b6b9a507111b"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing mothers</h2>
<p class="First">It is not known whether frovatriptan is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from FROVA, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
<p>In rats, oral dosing with frovatriptan resulted in levels of frovatriptan and/or its metabolites in milk up to four times higher than in plasma.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_d7c90df1-d0f4-442b-84ac-5127485f3587"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric use</h2>
<p class="First">The safety and effectiveness in pediatric patients have not been established. Therefore, FROVA is not recommended for use in patients under 18 years of age. There are no additional adverse reactions identified in pediatric patients based on postmarketing experience that were not previously identified in adults.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_bb7d09bd-1ea3-489b-af14-75971db7a0de"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric use</h2>
<p class="First">Mean blood concentrations of frovatriptan in elderly patients were 1.5- to 2-times higher than those seen in younger adults [ ].   No dosage adjustment is necessary.
                                    <span class="Italics">see Clinical Pharmacology ( )
                                        <a href="#LINK_56ef701b-33e0-478e-a330-83b102ec8a0a">12.3</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1b78d572-f72f-4145-ac91-becc5003352d"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First"> No dosage adjustment is necessary when FROVA is given to patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p>There is no clinical or pharmacokinetic experience with FROVA in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Because a greater than two-fold increase in AUC is predicted in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, there is a greater potential for adverse events in these patients, and FROVA should therefore be used with caution in that population.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_92447636-dd6e-448d-8b9e-9c8e1c1d2542"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">10 OVERDOSAGE</span></h1>
<p class="First">The elimination half-life of frovatriptan is 26 hours [ ]. Therefore, monitoring of patients after <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with frovatriptan should continue for at least 48 hours or while symptoms or signs persist. There is no specific antidote to frovatriptan.  It is unknown what effect hemodialysis or peritoneal dialysis has on the serum concentrations of frovatriptan.
                            <span class="Italics">see Clinical Pharmacology ( )
                                <a href="#LINK_56ef701b-33e0-478e-a330-83b102ec8a0a">12.3</a></span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_ca83a2c7-ddf1-44fb-a112-c6b6279662f4"></a><a name="section-10"></a><p></p>
<h1><span class="Bold">11 DESCRIPTION</span></h1>
<p class="First">FROVA (frovatriptan succinate) tablets contain frovatriptan succinate, a selective 5-hydroxy-tryptamine (5-HT ) receptor subtype agonist (triptan), as the active ingredient. Frovatriptan succinate is chemically designated as R-(+) 3-methylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole monosuccinate monohydrate and it has the following structure:
                            <span class="Sub">1</span><span class="Sub">1B/1D</span></p>
<p> 
                            <img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=35941e47-106d-414d-9529-0a56af7396d5&amp;name=frova-1.jpg"></p>
<p>The empirical formula is C H N O.C H O .H O, representing a molecular weight of 379.4. Frovatriptan succinate is a white to off-white powder that is soluble in water.
                            <span class="Sub">14</span><span class="Sub">17</span><span class="Sub">3</span><span class="Sub">4</span><span class="Sub">6</span><span class="Sub">4</span><span class="Sub">2</span></p>
<p>Each FROVA tablet for oral administration contains 3.91 mg frovatriptan succinate, equivalent to 2.5 mg of frovatriptan base. Each tablet also contains the inactive ingredients lactose NF, microcrystalline cellulose NF, colloidal silicon dioxide NF, sodium starch glycolate NF, magnesium stearate NF, hypromellose USP, polyethylene glycol 3000 USP, triacetin USP, and titanium dioxide USP.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_9b90571a-cce2-4284-9473-cce4312d17ac"></a><a name="section-11"></a><p></p>
<h1><span class="Bold">12 CLINICAL PHARMACOLOGY</span></h1>
<div class="Section" data-sectionCode="43679-0">
<a name="LINK_d6a5cbbb-ab0e-4535-8b05-0545267e15fe"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Frovatriptan binds with high affinity to 5-HT receptors. The therapeutic activity of FROVA is thought to be due to the agonist effects at the 5-HT receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.
                                    <span class="Sub">1B/1D</span><span class="Sub">1B/1D</span></p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_56ef701b-33e0-478e-a330-83b102ec8a0a"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of frovatriptan are similar in <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> patients and healthy subjects.</p>
<p><span class="Italics">Absorption</span></p>
<p>Mean maximum blood concentrations (C ) in patients are achieved approximately 2 - 4 hours after administration of a single oral dose of frovatriptan 2.5 mg. The absolute bioavailability of an oral dose of frovatriptan 2.5 mg in healthy subjects is about 20% in males and 30% in females. Food has no significant effect on the bioavailability of frovatriptan, but delays t by one hour.
                                    <span class="Sub">max</span><span class="Sub">max</span></p>
<p><span class="Italics">Distribution</span></p>
<p>Binding of frovatriptan to serum proteins is low (approximately 15%). Reversible binding to blood cells at equilibrium is approximately 60%, resulting in a blood: plasma ratio of about 2:1 in both males and females. The mean steady state volume of distribution of frovatriptan following intravenous administration of 0.8 mg is 4.2 L/kg in males and 3.0 L/kg in females.</p>
<p><span class="Italics">Metabolism</span></p>
<p>cytochrome P450 1A2 appears to be the principal enzyme involved in the metabolism of frovatriptan. Following administration of a single oral dose of radiolabeled frovatriptan 2.5 mg to healthy male and female subjects, 32% of the dose was recovered in urine and 62% in feces. Radiolabeled compounds excreted in urine were unchanged frovatriptan, hydroxylated frovatriptan, N-acetyl desmethyl frovatriptan, hydroxylated N-acetyl desmethyl frovatriptan and desmethyl frovatriptan, together with several other minor metabolites. Desmethyl frovatriptan has lower affinity for 5-HT receptors compared to the parent compound. The N-acetyl desmethyl metabolite has no significant affinity for 5-HT receptors. The activity of the other metabolites is unknown.
                                    <span class="Italics">In vitro,</span><span class="Sub">1B/1D</span></p>
<p><span class="Italics">Elimination</span></p>
<p>After an intravenous dose, mean clearance of frovatriptan was 220 and 130 mL/min in males and females, respectively. Renal clearance accounted for about 40% (82 mL/min) and 45% (60 mL/min) of total clearance in males and females, respectively. The mean terminal elimination half-life of frovatriptan in both males and females is approximately 26 hours.</p>
<p><span class="Bold"><span class="Underline">Special Populations</span></span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>The AUC of frovatriptan in patients with mild (Child-Pugh 5-6) to moderate (Child-Pugh 7-9) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> was about twice that of young, healthy subjects, but within the range observed in healthy elderly subjects and was considerably lower than the values attained with higher doses of frovatriptan (up to 40 mg), which were not associated with any serious adverse effects There is no clinical or pharmacokinetic experience with FROVA in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.
                                    <span class="Italics">.</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>The pharmacokinetics of frovatriptan following a single oral dose of 2.5 mg was not different in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (5 males and 6 females, creatinine clearance 16 - 73 mL/min) compared to subjects with normal renal function.</p>
<p><span class="Italics">Age</span></p>
<p>Mean AUC of frovatriptan was 1.5- to 2-fold higher in healthy elderly subjects (age 65 – 77 years) compared to those in healthy younger subjects (age 21 - 37 years). There was no difference in t or t between the two populations.
                                    <span class="Sub">max</span><span class="Sub">1/2</span></p>
<p><span class="Italics">Sex</span></p>
<p>There was no difference in the mean terminal elimination half-life of frovatriptan in males and females. Bioavailability was higher, and systemic exposure to frovatriptan was approximately 2-fold greater, in females than males, irrespective of age.</p>
<p><span class="Italics">Race</span></p>
<p>The effect of race on the pharmacokinetics of frovatriptan has not been examined.</p>
<p><span class="Bold">Drug Interaction Studies</span></p>
<p>Frovatriptan is not an inhibitor of human monoamine oxidase (MAO) enzymes or cytochrome P450 (isozymes 1A2, 2C9, 2C19, 2D6, 2E1, 3A4) at concentrations up to 250 to 500- fold higher than the highest blood concentrations observed in man at a dose of 2.5 mg. No induction of drug metabolizing enzymes was observed following multiple dosing of frovatriptan to rats or on addition to human hepatocytes . Although no clinical trials have been performed, it is unlikely that frovatriptan will affect the metabolism of co-administered drugs metabolized by these mechanisms.
                                    <span class="Italics">in vitro</span><span class="Italics">in vitro</span></p>
<p><span class="Italics">Oral Contraceptives</span></p>
<p>Retrospective analysis of pharmacokinetic data from females across trials indicated that the mean C and AUC of frovatriptan are 30% higher in those subjects taking oral contraceptives compared to those not taking oral contraceptives. 
                                    <span class="Sub">max</span></p>
<p><span class="Italics">Ergotamine</span></p>
<p>The AUC and C of frovatriptan (2 x 2.5 mg dose) were reduced by approximately 25% when co-administered with ergotamine tartrate .
                                    <span class="Sub">max</span><span class="Italics">[see Contraindications ( ), Drug Interactions ( )]
                                        <a href="#LINK_12cd4ef2-79d2-406e-a549-15548debcebb">4</a><a href="#LINK_34918c27-9b47-48fa-991b-3d55ce303526">7.1</a></span></p>
<p><span class="Italics">Propranolol</span></p>
<p>Propranolol increased the AUC of frovatriptan 2.5 mg in males by 60% and in females by 29%. The C of frovatriptan was increased 23% in males and 16% in females in the presence of propranolol. The t as well as half-life of frovatriptan, though slightly longer in the females, were not affected by concomitant administration of propranolol.
                                    <span class="Sub">max</span><span class="Sub">max</span></p>
<p><span class="Italics">Moclobemide</span></p>
<p>The pharmacokinetic profile of frovatriptan was unaffected when a single oral dose of frovatriptan 2.5 mg was administered to healthy female subjects receiving the MAO-A inhibitor, moclobemide, at an oral dose of 150 mg bid for 8 days.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_b56be839-47d4-440f-b953-2f1aab6ab6c1"></a><a name="section-12"></a><p></p>
<h1><span class="Bold">13 NONCLINICAL TOXICOLOGY</span></h1>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_bc73ffdd-a3ba-4d90-b44b-d9bd5a4aa5c4"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Italics">Carcinogenesis</span></p>
<p>The carcinogenic potential of orally administered frovatriptan was evaluated in an 84-week study in mice (4, 13, and 40 mg/kg/day), a 104-week study in rats (8.5, 27 and 85 mg/kg/day), and a 26-week study in p53(+/-) transgenic mice (20, 62.5, 200, and 400 mg/kg/day). Although a maximum tolerated dose was not achieved in the 84-week mouse study and in female rats, plasma exposures at the highest doses studied were higher than that achieved in humans at the maximum recommended human dose (MRHD) of 7.5 mg/day. There were no increases in tumor incidence in the 84-week mouse study at doses producing plasma exposures (AUC) 140 times that in humans at the MRHD. In the rat study, there was a statistically significant increase in the incidence of <span class="product-label-link" type="condition" conceptid="437251" conceptname="Benign neoplasm of pituitary gland and craniopharyngeal duct">pituitary adenomas</span> in males only at 85 mg/kg/day, a dose associated with a plasma AUC 250 times that in humans at the MRHD. In the 26-week p53(+/-) transgenic mouse study, the incidence of subcutaneous <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcomas</span> was increased in females at doses of 200 and 400 mg/kg/day.</p>
<p>These <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcomas</span> were associated with subcutaneously implanted animal identification transponders, and are not considered to be relevant to humans. There were no other increases in tumor incidence of any type in any dose group.</p>
<p><span class="Italics">Mutagenesis</span></p>
<p>Frovatriptan was clastogenic in human lymphocyte cultures, in the absence of metabolic activation. In the bacterial reverse mutation assay (Ames test), frovatriptan produced an equivocal response in the absence of metabolic activation. Frovatriptan was negative in an mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay and an mouse bone marrow micronucleus test.
                                    <span class="Italics">in vitro</span><span class="Italics">tk</span><span class="Italics">in vivo</span></p>
<p><span class="Italics">Impairment of Fertility</span></p>
<p>Male and female rats were dosed orally with frovatriptan prior to and during mating and in females up to implantation, at doses of 100, 500, and 1000 mg/kg/day (equivalent to approximately 130, 650, and 1300 times the MRHD on a mg/m basis). At all dose levels, there was an increase in the number of females that mated on the first day of pairing compared to control animals. This occurred in conjunction with a prolongation of the estrous cycle. In addition, females had a decreased mean number of corpora lutea, and consequently a lower number of live fetuses per litter, which suggested a partial impairment of ovulation. There were no other fertility-related effects.
                                    <span class="Sup">2</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_fcfd1052-1a76-4beb-9a2b-82f43ec81daf"></a><a name="section-13"></a><p></p>
<h1><span class="Bold">14 CLINICAL STUDIES</span></h1>
<p class="First">The efficacy of FROVA in the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> was demonstrated in four randomized, double-blind, placebo-controlled, short-term outpatient trials. In these trials, patients received doses of frovatriptan from 0.5 mg to 40 mg. In these controlled short-term trials, patients were predominately female (88%) and Caucasian (94%) with a mean age of 42 years (range 18 - 69). Patients were instructed to treat a moderate to severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> response, defined as a reduction in <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> severity from moderate or severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> to mild or no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, was assessed for up to 24 hours after dosing. The associated symptoms <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span> and <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">phonophobia</span> were also assessed. Maintenance of response was assessed for up to 24 hours post dose. In two of the trials a second dose of FROVA was provided after the initial treatment, to treat recurrence of the <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> within 24 hours. Other medication, excluding other 5-HT agonists and ergotamine containing compounds, was permitted from 2 hours after the first dose of FROVA. The frequency and time to use of additional medications were also recorded.
                            <span class="Sub">1</span></p>
<p>In all four placebo-controlled trials, the percentage of patients achieving a <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response 2 hours after treatment was significantly greater for those taking FROVA 2.5 mg compared to those taking placebo (Table 2).</p>
<p>Lower doses of frovatriptan (1 mg or 0.5 mg) were not effective at 2 hours. Higher doses (5 mg to 40 mg) of frovatriptan showed no added benefit over 2.5 mg but did cause a greater incidence of adverse events.</p>
<p><span class="Bold">Table 2 Percentage of Patients with <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> Response (Mild or No <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>) 2 Hours Following Treatment
                                <br><span class="Sup">a</span></span></p>
<table>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Trial</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">FROVA</span><span class="Bold">2.5 mg</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Placebo</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">42%* (n=90)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">22% (n=91)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">39%* (n=187)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">21% (n=99)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">46%** (n=672)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">27% (n=347)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">37%** (n=438)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">23% (n=225)</p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule Toprule" colspan="3" valign="top"><p class="First">ITT observed data, excludes patients who had missing data or were asleep; *p&lt;0.05, **p&lt;0.001 in comparison with placebo
                                            <span class="Sup">a</span></p></td></tr>
</tbody>
</table>
<p>The estimated probability of achieving an initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response by 2 hours following treatment is depicted in Figure 1.</p>
<p><span class="Bold">Figure 1 Estimated Probability of Achieving Initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> Response Within 2 Hours
                                <br></span></p>
<div class="Figure"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=35941e47-106d-414d-9529-0a56af7396d5&amp;name=frova-2.jpg"></div>
<p><span class="Italics">Figure 1 shows a Kaplan-Meier plot of the probability over time of obtaining <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response (no or mild <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>) following treatment with FROVA 2.5 mg or placebo. The probabilities displayed are based on pooled data from the four placebo-controlled trials described in Table 2. Patients who did not achieve a response were censored at 24 hours.</span></p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>-associated <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span> and <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">phonophobia</span> at baseline there was a decreased incidence of these symptoms in FROVA treated patients compared to placebo.</p>
<p>The estimated probability of patients taking a second dose or other medication for their <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> over the 24 hours following the initial dose of study treatment is summarized in Figure 2.</p>
<p><span class="Bold">Figure 2 Estimated Probability of Patients Taking a Second Dose or Other Medication for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> Over the 24 Hours Following the Initial Dose of Study Treatment
                                <br><br></span></p>
<div class="Figure"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=35941e47-106d-414d-9529-0a56af7396d5&amp;name=frova-3.jpg"></div>
<p><span class="Italics">Figure 2 is a Kaplan-Meier plot showing the probability of patients taking a second dose or other medication for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> over the 24 hours following the initial dose of study medication based on the data from the four placebo-controlled trials described in Table 2. The plot includes those patients who had a response to the initial dose and those who did not. The protocols did not permit remedication within 2 hours of the initial dose.</span></p>
<p>Efficacy was unaffected by a history of <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span>; gender; age, or concomitant medications commonly used by <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> patients.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_b292195f-14e0-4a23-8756-29fc4f1d8062"></a><a name="section-14"></a><p></p>
<h1><span class="Bold">16 HOW SUPPLIED/STORAGE AND HANDLING</span></h1>
<p class="First">NDC:50436-0026-1 in a BOTTLE of 9 TABLET, FILM COATEDS</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_60d67f42-ea71-4862-8b20-5ee71913d8de"></a><a name="section-15"></a><p></p>
<h1><span class="Bold">17 PATIENT COUNSELING INFORMATION</span></h1>
<p class="First">See FDA-Approved Patient Labeling (Patient Information)</p>
<p><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span> and/or <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">Infarction</span>, Prinzmetal’s Angina, Other Vasospastic Reactions, and Cerebrovascular Events</span></span></p>
<p>Inform patients that FROVA may cause serious cardiovascular adverse reactions such as <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  Although serious cardiovascular reactions can occur without warning symptoms, instruct patients to be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, slurring of speech, and instruct them to ask for medical advice when observing any indicative sign or symptoms.  Instruct patients to seek medical advice if they have symptoms of other vasospastic reactions
                            <span class="Italics">[see Warnings and Precautions ( , , , , and )].
                                <a href="#LINK_87a7b537-4900-4e58-ba02-36b2cc7ae264">5.1</a><a href="#LINK_b222c1ac-4794-4ae0-972d-dd36bab90284">5.2</a><a href="#LINK_0f5a86c8-9aba-4622-b8bc-5655902910c5">5.4</a><a href="#LINK_56de01ef-1231-4672-bb67-a3d877257436">5.5</a><a href="#LINK_4fdf5f3e-5c81-4c7c-b9ff-d1841c63b984">5.8</a></span></p>
<p><span class="Bold"><span class="Underline">Anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></span></span></p>
<p>Inform patients that anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have occurred in patients receiving FROVA. Such reactions can be life threatening or fatal. In general, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to drugs are more likely to occur in individuals with a history of sensitivity to multiple allergens
                            <span class="Italics">[see Contraindications ( )].
                                <a href="#LINK_12cd4ef2-79d2-406e-a549-15548debcebb">4</a></span></p>
<p><span class="Bold"><span class="Underline">Medication Overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></span></span></p>
<p>Inform patients that use of drugs to treat <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">acute migraines</span> for 10 or more days per month may lead to an exacerbation of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and encourage patients to record <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> frequency and drug use (e.g., by keeping a <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> diary)
                            <span class="Italics">[see Warnings and Precautions ( )].
                                <a href="#LINK_e293fcd4-96c4-4393-8ddf-cec3e8cf073a">5.6</a></span></p>
<p><span class="Bold"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></span></span></p>
<p>Inform patients about the risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with the use of FROVA or other triptans, particularly during combined use with SSRIs, SNRIs, TCAs, and MAO inhibitors
                            <span class="Italics">[see Warnings and Precautions ( ) and Drug Interactions ( )].
                                <a href="#LINK_d9d35ee9-ca30-4276-a75e-cb3211ca2357">5.7</a><a href="#LINK_70973a58-9917-4e1a-8ff0-0af5224c2f8a">7.3</a></span></p>
<p><span class="Bold"><span class="Underline">Pregnancy</span></span></p>
<p>Inform patients that FROVA should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus
                            <span class="Italics">[see Use in Specific Populations ( )].
                                <a href="#LINK_c9051e96-6a54-4b4a-8cba-0def75f4877e">8.1</a></span></p>
<p><span class="Bold"><span class="Underline">Nursing Mothers</span></span></p>
<p>Inform patients to notify their healthcare provider if they are breastfeeding or plan to breastfeed
                            <span class="Italics">[see Use in Specific Populations ( )].
                                <a href="#LINK_2d9af56a-1e92-4b1c-9bac-b6b9a507111b">8.3</a></span></p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="LINK_47bf5fa2-57ef-453c-8c93-747c512c2066"></a><a name="section-16"></a><p></p>
<h1><span class="Bold">PATIENT LABELING</span></h1>
<p class="First"><span class="Bold">Patient Information
                                <br></span><span class="Bold">FROVA
                                <span class="Sup">®</span></span><span class="Bold">  (FRO-va) (frovatriptan succinate) Tablets
                                <br><br></span></p>
<p>Read this Patient Information before you start taking FROVA and each time you get a refill.  There may be new information. This information does not take the place of talking with your doctor.  You and your doctor should discuss FROVA when you start taking your medication and at regular check-ups.</p>
<p><span class="Bold">What is</span><span class="Bold">FROVA?</span></p>
<p>FROVA is a prescription medicine used to treat <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> in adults.</p>
<p>FROVA is not used to treat other types of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>.</p>
<p>FROVA is not used to prevent or decrease the number of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span>.</p>
<p>It is not known if FROVA is safe and effective to treat <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headaches</span>.</p>
<p>It is not known if FROVA is safe and effective in children under 18 years of age.  </p>
<p><span class="Bold">Who should not take</span><span class="Bold">FROVA?</span></p>
<p><span class="Bold">Do not take FROVA if you have:</span></p>
<ul class="Disk">
<li>heart problems, a history of heart problems, or problems with the electrical system of your heart</li>
<li>had a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="373503" conceptname="Transient cerebral ischemia">transient ischemic attacks</span> (TIAs), or problems with your blood circulation</li>
<li>hemiplegic <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span> or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span>.  If you are not sure if you have these types of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span>, ask your healthcare provider.</li>
<li>narrowing of blood vessels to your legs, arms, or stomach (<span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span>)</li>
<li>uncontrolled high blood pressure</li>
<li>taken any of the following medicines in the last 24 hours:
                                <ul class="Circle">
<li>almotriptan (AXERT )
                                        <span class="Sup">®</span>
</li>
<li>eletriptan (RELPAX )
                                        <span class="Sup">®</span>
</li>
<li>naratriptan (AMERGE )
                                        <span class="Sup">®</span>
</li>
<li>rizatriptan (MAXALT , MAXALT-MLT )
                                        <span class="Sup">®</span><span class="Sup">®</span>
</li>
<li>sumatriptan (IMITREX , SUMAVEL DosePro , ALSUMA )
                                        <span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span>
</li>
<li>sumatriptan and naproxen (TREXIMET )
                                        <span class="Sup">®</span>
</li>
<li>zolmitriptan (ZOMIG )
                                        <span class="Sup">®</span>
</li>
<li>Ergotamine or ergotamine-type medicines (BELLERGAL , CAFERGOT , ERGOMAR , WIGRAINE , D.H.E.45 , MIGRANAL , SANSERT ) Ask your healthcare provider if you are not sure if your medicine is listed above.
                                        <span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span><br>
</li>
</ul>
</li>
<li>an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to frovatriptan or any of the ingredients in FROVA.  See the end of this leaflet for a complete list of ingredients in FROVA.</li>
</ul>
<p><span class="Bold">What should I tell my doctor before taking</span><span class="Bold">FROVA?</span></p>
<p>Before you take FROVA, tell your doctor about all of your medical conditions, including if you:</p>
<ul class="Disk">
<li>have high blood pressure</li>
<li>have high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span></li>
<li>have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></li>
<li>smoke</li>
<li>are overweight</li>
<li>are a female who has gone through <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span></li>
<li>have heart disease or a family history of heart disease or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></li>
<li>are pregnant or plan to become pregnant</li>
<li>are breastfeeding or plan to breastfeed</li>
</ul>
<p>including prescription and nonprescription medicines, vitamins, and herbal supplements.
                            <span class="Bold">Tell your doctor about all the medicines you take,</span></p>
<p>Especially tell your doctor if you take:</p>
<ul class="Disk">
<li>propranolol</li>
<li>selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs), two types of drugs for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or other disorders.  Common SSRIs are CELEXA (citalopram HBr), LEXAPRO (escitalopram oxalate), PAXIL (paroxetine), PROZAC /SARAFEM (fluoxetine), SYMBAX (olanzapine/fluoxetine), ZOLOFT (sertraline), and fluvoxamine.  Common SNRIs are CYMBALTA (duloxetine) and EFFEXOR (venlafaxine).
                                <span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span>
</li>
</ul>
<p>These medicines may affect how FROVA works, or FROVA may affect how these medicines work.</p>
<p>Ask your doctor or pharmacist for a list of these medicines if you are not sure.</p>
<p>Know the medicines you take.  Keep a list of them to show your doctor or pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take</span><span class="Bold">FROVA?</span></p>
<ul class="Disk">
<li>Certain people should take their first dose of FROVA in their doctor’s office or in another medical setting.  Ask your doctor if you should take your first dose in a medical setting.</li>
<li>Take FROVA exactly as your doctor tells you.</li>
<li>If you do not get any relief after your first FROVA tablet, do not take a second tablet without first talking with your doctor.</li>
<li>If your <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> comes back or you only get some relief from your <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, you may take a second FROVA tablet 2 hours after the first tablet.</li>
<li>Do not take more than 3 FROVA tablets in a 24-hour period.</li>
<li>It is not known if it is safe and effective to take FROVA for more than 4 <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> in 30 days.</li>
<li>If you take too much FROVA, call your doctor or go to the nearest hospital emergency room right away.</li>
<li>You should write down when you have <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> and when you take FROVA so you can talk with your doctor about how FROVA is working for you.</li>
</ul>
<p><span class="Bold">What should I avoid while taking FROVA?</span></p>
<p>FROVA can cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>.  If you have these symptoms do not drive a car, use machinery, or do anything where you need to be alert.</p>
<p><span class="Bold">What are the possible side effects of</span><span class="Bold">FROVA?</span></p>
<p><span class="Bold">FROVA can cause serious side effects.</span></p>
<p>Call your doctor right away if you have any of the following symptoms after taking FROVA:</p>
<ul class="Disk">
<li>  Heart problems may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Stop taking FROVA and get emergency medical help right away if you have any of the following symptoms of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or other heart problems:
                                <span class="Bold"><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Heart attack</span> or other heart problems.</span><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">Discomfort</span> in the center of your chest that lasts for more than a few minutes, or that goes away and comes back</li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span> or <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span> that feels like heavy pressure, squeezing, or fullness</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> in your arms, back, neck, jaw, or stomach</li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Shortness of breath</span> with or without <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span></li>
<li>Breaking out in a <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">cold sweat</span></li>
<li>Feeling lightheaded</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> with any of the symptoms included above</li>
</ul>
</li>
<li>  Symptoms of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> include face drooping, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>, and unusual <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>.
                                <span class="Bold"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span>.</span>
</li>
<li>
<span class="Bold">Changes in color or sensation in your fingers and toes</span><span class="Bold">(Raynaud’s syndrome).</span>
</li>
<li>(gastrointestinal and colonic ischemic events). Symptoms of gastrointestinal and colonic ischemic events include:
                                <span class="Bold">Stomach and intestinal problems</span><ul class="Circle">
<li>Sudden or severe <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Stomach pain</span> after meals</li>
<li><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight loss</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">Bloody diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></li>
</ul>
</li>
<li>(peripheral vacular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>). Symptoms of peripheral vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> include:
                                <span class="Bold">Problems with blood circulation to your legs and feet</span><ul class="Circle">
<li>Cramping and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your legs or hips</li>
<li>Feeling of heaviness or tightness in your leg muscles</li>
<li>Burning or aching <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your feet or toes while resting</li>
<li><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in your legs</li>
<li><span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">Cold</span> feeling or color changes in one or both legs or feet</li>
</ul>
</li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">Increased blood pressure</span></span></li>
<li>Symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> include:
                                <span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span>. </span><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></li>
<li><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Hives</span></li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">Itching</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span> of the face, mouth, throat, or tongue</li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Difficulty breathing</span></li>
</ul>
</li>
<li>Some people who use too many FROVA tablets may have worse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> (medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>).  If your <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> get worse, your doctor may decide to stop your treatment with FROVA.
                                <span class="Bold">Medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> is a rare but serious problem that can happen in people using FROVA, especially if FROVA is used with anti-depressant medicines called SSRIs and SNRIs.  Call your doctor right away if you have any of the following symptoms of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>:
                                <span class="Bold"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span>.</span><ul class="Circle">
<li>Mental changes such as seeing things that are not there (<span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>), <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span></li>
<li>Fast heartbeat</li>
<li>Changes in blood pressure</li>
<li>High body temperature</li>
<li>Tight muscles</li>
<li>Trouble walking</li>
</ul>
</li>
</ul>
<p>The most common side effects of FROVA are:</p>
<ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (other than a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> (feeling of <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span></li>
<li><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> (<span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="4141161" conceptname="Hot">feeling hot</span> or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span></li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> (<span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">skeletal pain</span> (<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">pain in joints</span> or bones)</li>
</ul>
<p>Tell your doctor about any symptoms that you develop while taking FROVA.</p>
<p><span class="Bold">This is not a complete list of side effects.  Talk to your doctor if you develop any symptoms that concern you.</span></p>
<p><span class="Bold">How should I store FROVA?</span></p>
<p>Store FROVA at between 59°F to 86°F (15°C to 30°C).  Protect FROVA from moisture.  Discard after expiration date printed on package.</p>
<p><span class="Bold">Keep FROVA and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General advice about the safe and effective use of FROVA.</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets.  Do not use FROVA for a condition for which it was not prescribed. Do not give FROVA to other people, even if they have the same symptoms as you. People may be harmed if they take medicines that have not been prescribed for them.</p>
<p>This leaflet summarizes the most important information about FROVA. If you would like more information about FROVA, talk to your doctor. You can ask your doctor or pharmacist for information on FROVA that is written for healthcare professionals. You can also call 1-800-462-3636 or visit our website at www.FROVA.com.</p>
<p><span class="Bold">What are the Ingredients in FROVA?</span></p>
<p>Active ingredient:  frovatriptan succinate</p>
<p>Inactive ingredients:  lactose NF, microcrystalline cellulose NF, colloidal silicon dioxide NF, sodium starch glycolate NF, magnesium stearate NF, hypromellose USP, polyethylene glycol 3000 USP, triacetin USP, and titanium dioxide USP</p>
<p>Manufactured for:  Endo Pharmaceuticals Inc., Malvern, PA 19355</p>
<p>Manufactured by: Almac Pharma Services Limited, Craigavon, BT63 5UA, UK</p>
<p>FROVA is a registered trademark of Vernalis Development Limited.</p>
<p>© 2013 Endo Pharmaceuticals Inc. All rights reserved.</p>
<p>U.S. Patent Nos 5,962,501, 5,827,871, 5,637,611 and 5,464,864 and 5,616,603.</p>
<p>APX1009/1</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>FROVA (FROVATRIPTAN SUCCINATE) TABLET, FILM COATED</h1>
<div class="Figure"><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=35941e47-106d-414d-9529-0a56af7396d5&amp;name=50436-0026.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FROVA 		
					</strong><br><span class="contentTableReg">frovatriptan succinate tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50436-0026(NDC:63481-025)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FROVATRIPTAN SUCCINATE</strong> (FROVATRIPTAN) </td>
<td class="formItem">FROVATRIPTAN</td>
<td class="formItem">2.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">E;2;5</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50436-0026-1</td>
<td class="formItem">9  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021006</td>
<td class="formItem">11/08/2001</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Unit Dose Services
							(831995316)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Unit Dose Services (831995316)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Unit Dose Services</td>
<td class="formItem"></td>
<td class="formItem">831995316</td>
<td class="formItem">REPACK(50436-0026)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>96af229a-fee6-4de8-9dac-fb339ca79330</div>
<div>Set id: 35941e47-106d-414d-9529-0a56af7396d5</div>
<div>Version: 2</div>
<div>Effective Time: 20131029</div>
</div>
</div> <div class="DistributorName">Unit Dose Services</div></p>
</body></html>
